[Long-term results of conservative management of reflux esophagitis].
Reflux esophagitis is a frequent and chronic disease. Impairment of the quality of life by the reflux symptoms and the risk of complications are the most important indications for a long-term treatment. The base of the treatment of reflux esophagitis is the inhibition of the gastric acid secretion with proton pump inhibitors (PPI) or by H2-receptor antagonist. In general, PPI's are more efficient in the treatment of refluxesophagitis as compared to H2-receptor antagonists blockers regarding the relieve of symptoms and the healing of erosive esophageal lesions. The use of an antacids and procinetics in the long-term treatment is not indicated. The treatment strategy depends on the severity of the symptoms and the esophageal lesions. Patient with mild esophagitis can be treated either with H2-receptor antagonists or with PPI's on demand or continuous. In the case of severe esophagitis, a long-term treatment with PPI's is indicated to avoid complications. Recurrence of esophagitis during a long-term therapy should be treated by PPI's. After healing the long-term treatment should be adapted either by increasing the given dose of the medicament or by a switch to more effective medicaments in acid suppression.
Viani
F
F
Abteilung für Gastroenterologie, CHUV, Lausanne.
Dorta
G
G
D000367:Age Factors; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004032:Diet; D004359:Drug Therapy, Combination; D004942:Esophagitis, Peptic / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000150:complications*; D006801:Humans; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D009853:Omeprazole